8-K: BioAffinity Strengthens Advisory Board with Top Lung Cancer Experts

BioAffinity Technologies announced the appointment of three nationally recognized pulmonary and lung cancer authorities to its Medical and Scientific Advisory Board to guide strategic priorities and CyPath Lung adoption.

Summary

• bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW) appointed David Ost, MD, MPH, Daniel Sterman, MD, and J. Scott Ferguson, MD, to its Medical and Scientific Advisory Board on February 9, 2026.
• These appointments are part of a planned expansion to align with the company's clinical, scientific, and commercial priorities, including the ongoing integration of CyPath Lung, a noninvasive diagnostic test for lung cancer, into the standard of care for indeterminate pulmonary nodules.
• CyPath Lung has demonstrated 92% sensitivity, 87% specificity, and 88% accuracy in detecting lung cancer in high-risk patients with small indeterminate lung nodules (less than 20 millimeters).
• The new board members are recognized leaders in interventional pulmonology, thoracic oncology, critical care, gene therapy, immunotherapy for lung cancer, and advanced diagnostic techniques.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong positive development, as the addition of highly respected medical experts significantly enhances the company's scientific and clinical credibility, which is crucial for the adoption of its diagnostic product.

Positives

• The appointment of three highly respected and nationally recognized experts in pulmonary medicine and lung cancer significantly strengthens the Medical and Scientific Advisory Board.
• The new board members bring extensive experience in interventional pulmonology, thoracic oncology, critical care, and advanced diagnostic techniques, which is directly relevant to the company's mission.
• The expansion of the advisory board is intended to provide independent guidance on strategic priorities, including increasing the adoption of the CyPath Lung diagnostic test.
• CyPath Lung has demonstrated strong performance with 92% sensitivity, 87% specificity, and 88% accuracy in detecting early-stage lung cancer in high-risk patients.

Risks

• Actual results could differ materially from current expectations due to various risks and uncertainties.
• Important factors that could cause actual results to differ materially include, among others, the contributions of Drs. Ost, Sterman, and Ferguson to the Company.
• Further risks are discussed in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, and its subsequent filings with the SEC.

Future Outlook

The company anticipates that the expertise of the newly appointed Medical and Scientific Advisory Board members will be instrumental in guiding its work to advance CyPath Lung as a vital diagnostic tool for early-stage lung cancer detection in high-risk patients. Management expects their advice and counsel to support clinical implementation and broader adoption of the diagnostic platform.

Management Comments

• "Our Medical and Scientific Advisory Board's extensive experience in real-world pulmonary practice and lung health supports our corporate and clinical mission to improve outcomes for patients by detecting lung cancer at the earliest stages when it is most treatable and survivable." Gordon Downie, MD, PhD, bioAffinity Technologies Chief Medical Officer.
• "These appointments strengthen our panel of clinical and scientific leaders helping to guide our work as we continue to advance CyPath Lung as a vital diagnostic tool to detect lung cancer at an early stage in high-risk patients." Maria Zannes, President and CEO of bioAffinity Technologies.
• "Their advice and counsel will be instrumental as we focus on clinical implementation and broader adoption of our diagnostic platform." Maria Zannes, President and CEO of bioAffinity Technologies.

Industry Context

StockSavvy.ai notes that the appointment of highly credentialed experts to a medical advisory board is a common strategy for biotechnology companies, particularly those in diagnostics, to bolster scientific credibility and accelerate market adoption. In the competitive landscape of lung cancer diagnostics, where early detection significantly improves patient outcomes, leveraging key opinion leaders like Drs. Ost, Sterman, and Ferguson can be crucial for validating a noninvasive test like CyPath Lung and integrating it into clinical practice. This move positions bioAffinity to better navigate clinical challenges and gain trust within the medical community, potentially enhancing its competitive standing against other diagnostic solutions.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Potentially positive impact due to enhanced credibility, improved strategic guidance, and increased likelihood of CyPath Lung adoption, which could lead to future revenue growth.
• Patients: Positive impact through improved early detection of lung cancer, leading to better treatment outcomes and survivability.
• Clinicians: Provides access to a noninvasive diagnostic tool (CyPath Lung) supported by a highly reputable advisory board, potentially increasing confidence in its use.
• Employees: May benefit from increased company stability and growth prospects due to strengthened strategic direction.

Next Steps

• Ongoing integration of CyPath Lung into the standard of care for indeterminate pulmonary nodules.
• Focus on clinical implementation and broader adoption of the CyPath Lung diagnostic platform.

Key Dates

Recommendation

The appointment of three highly respected and nationally recognized experts to the Medical and Scientific Advisory Board significantly enhances bioAffinity's scientific credibility and strategic capabilities. This move is crucial for driving the adoption of its promising CyPath Lung diagnostic test, which has demonstrated high accuracy in early lung cancer detection. Such a strengthening of leadership is a strong positive signal for future growth and market penetration, making the stock an attractive 'buy' for investors looking for long-term potential in the biotechnology diagnostics sector.

Keywords

lung cancer diagnosis, noninvasive diagnostic, CyPath Lung, biotechnology, medical advisory board, early cancer detection, pulmonary medicine, interventional pulmonology, thoracic oncology, AI diagnostics, flow cytometry